Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2026)

Vir Biotechnology's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $274.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed 0.22% year-over-year to $274.2 million; the TTM figure through Mar 2026 stood at $274.2 million (changed 0.22% YoY), while the FY2025 annual figure was $232.2 million, up 159.76% from the prior year.
• Cash & Equivalents came in at $274.2 million for Q1 2026 at Vir Biotechnology, up from $232.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $963.7 million in Q3 2022 to a low of $11.0 million in Q1 2023.
• A 5-year average of $307.1 million and a median of $232.2 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 9774.69% in 2022 and plunged 98.65% in 2023, its largest moves.
• Vir Biotechnology's Cash & Equivalents stood at $848.6 million in 2022, then slumped by 71.53% to $241.6 million in 2023, then plunged by 63.0% to $89.4 million in 2024, then jumped by 159.76% to $232.2 million in 2025, then advanced by 18.08% to $274.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $274.2 million, $232.2 million, and $170.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison